Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading Volume – What’s Next?

Posted by Brian Himes on May 19th, 2026

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 469,406 shares changed hands during mid-day trading, an increase of 10% from the previous session’s volume of 426,898 shares.The stock last traded at $10.43 and had previously closed at $10.70.

Analysts Set New Price Targets

Several research analysts recently issued reports on DSGN shares. Oppenheimer upped their target price on shares of Design Therapeutics from $18.00 to $21.00 and gave the stock an “outperform” rating in a research report on Monday, May 4th. Jefferies Financial Group assumed coverage on Design Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $15.00 price target for the company. Wall Street Zen upgraded Design Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Piper Sandler reiterated an “overweight” rating and set a $20.00 price objective on shares of Design Therapeutics in a research report on Wednesday, April 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Design Therapeutics in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Design Therapeutics has an average rating of “Moderate Buy” and an average target price of $16.50.

Check Out Our Latest Stock Report on Design Therapeutics

Design Therapeutics Price Performance

The stock’s 50 day moving average is $12.18 and its 200-day moving average is $10.30. The company has a market capitalization of $670.95 million, a P/E ratio of -8.93 and a beta of 1.73.

Design Therapeutics (NASDAQ:DSGN – Get Free Report) last posted its earnings results on Tuesday, April 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.07. On average, equities research analysts anticipate that Design Therapeutics, Inc. will post -1.36 EPS for the current year.

Hedge Funds Weigh In On Design Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. DLD Asset Management LP bought a new position in Design Therapeutics in the 3rd quarter worth about $376,000. Strs Ohio purchased a new position in Design Therapeutics in the 1st quarter worth approximately $87,000. Public Employees Retirement System of Ohio purchased a new stake in Design Therapeutics during the 4th quarter valued at $67,000. Invesco Ltd. raised its stake in shares of Design Therapeutics by 26.8% in the second quarter. Invesco Ltd. now owns 14,364 shares of the company’s stock worth $48,000 after purchasing an additional 3,033 shares during the last quarter. Finally, Quantinno Capital Management LP bought a new position in shares of Design Therapeutics during the first quarter valued at $150,000. Institutional investors own 56.64% of the company’s stock.

About Design Therapeutics

(Get Free Report)

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.